Effects of Selective Serotonin Reuptake Inhibitor Therapy on Endothelial Function and Inflammatory Markers in Patients With Coronary Heart Disease
| Autor: | Grazia Maria Costa, Stefano Mancini, Lamberto Manzoli, L. Angeloni, Fiorella Fontana, Carmine Pizzi |
|---|---|
| Přispěvatelé: | C. Pizzi, S.Mancini, L. Angeloni, F. Fontana, L. Manzoli, GM. Costa. |
| Rok vydání: | 2009 |
| Předmět: |
Male
medicine.medical_specialty Endothelium SELECTIVE SEROTONIN REUPTAKE INHIBITOR THERAPY Serotonin reuptake inhibitor ENDOTHELIAL FUNCTION Socio-culturale Coronary Disease Inflammation Placebo Gastroenterology Coronary artery disease Double-Blind Method Sertraline Internal medicine medicine Humans Pharmacology (medical) Aged Psychiatric Status Rating Scales Pharmacology Depression Interleukin-6 business.industry Beck Depression Inventory Middle Aged medicine.disease Vasodilation Endothelial stem cell C-Reactive Protein Endocrinology medicine.anatomical_structure CORONARY ARTERY DISEASE Female Endothelium Vascular medicine.symptom business Selective Serotonin Reuptake Inhibitors Follow-Up Studies medicine.drug |
| Zdroj: | Clinical Pharmacology & Therapeutics. 86:527-532 |
| ISSN: | 1532-6535 0009-9236 |
| Popis: | We investigated the effect of sertraline on inflammation and endothelial function in patients with coronary heart disease (CHD) and symptoms of depression. One hundred patients with CHD and depression were randomized in a double-blind fashion to receive sertraline or a placebo. We measured symptoms of depression (Beck Depression Inventory (BDI) score), levels of inflammatory markers (C-reactive protein (CRP) and interleukin-6 (IL-6)), and flow-dependent endothelium-mediated dilation (FMD) before and after 20 weeks of treatment. Sertraline treatment significantly reduced the BDI score as compared with both baseline and placebo. Levels of CRP and IL-6 also decreased after 20 weeks of sertraline treatment, whereas they did not significantly change in the placebo group. There was a significant improvement in FMD in patients on sertraline treatment, whereas there was no change in FMD in the placebo group. Sertraline improves endothelial function and reduces inflammatory markers in patients with CHD and symptoms of depression. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Plný text